Jacqueline Vuong

Jacqueline Vuong

Auto-generated profile, based on publicly available information

Jacqueline Vuong

Boston University School of Medicine, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2017 in Science
Verified
Journal Article
Closed access
PDF file
JFJosé Javier Fuster
José Javier Fuster
SMSusan MacLauchlan
Susan MacLauchlan
MZMaría A. Zuriaga
María A. Zuriaga
MPMaya N. Polackal
Maya N. Polackal
AOAllison C. Ostriker
Allison C. Ostriker
KWKenneth Walsh
Kenneth Walsh
Faulty blood cells and heart disease: Recent studies have shown that elderly people's blood cells often harbor mutations in genes encoding certain epigenetic regulators. These mutations can lead to clonal expansion of the mutant blood cells, which increases the risk of blood cancers and cardiovascular disease. Fuster et al. generated a mouse model to investigate how one of these genes, Tet2 , affects atherosclerosis development (see the Perspective by Zhu et al. ). They found that the disease progressed more rapidly in mice transplanted with Tet2 -deficient bone marrow cells. This was due to increased secretion of interleukin-1β by Tet2 -deficient macrophages in a process that depended on the action of inflammasomes. Science , this issue p. 842 ; see also p. 798

1 February 2019 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
JVJacqueline T Vuong
Jacqueline T Vuong
SJSophia Jacob
Sophia Jacob
KAKevin M Alexander
Kevin M Alexander
ASAvinainder Singh
Avinainder Singh
RLRonglih Liao
Ronglih Liao
SDSharmila Dorbala
Sharmila Dorbala

7 June 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DDDuy Dao
Duy Dao
JVJacqueline T Vuong
Jacqueline T Vuong
LALorenzo Anez-Bustillos
Lorenzo Anez-Bustillos
APAmy Pan
Amy Pan
PMPaul D Mitchell
Paul D Mitchell
MPMark Puder
Mark Puder
Vascular endothelial growth factor (VEGF) has previously been demonstrated to accelerate compensatory lung growth (CLG) in mice and may be a useful therapy for pulmonary hypoplasia. Systemic administration of VEGF can result in side effects such as hypotension and edema. The aim of this study was to explore nasal delivery as a route for intrapulmonary VEGF administration. Eight-week-old C57BL/6 male mice underwent left pneumonectomy, followed by daily nasal instillation of VEGF at 0.5 mg/kg or isovolumetric saline. Lung volume measurement, morphometric analysis, and protein expression studies were performed on lung tissues harvested on postoperative day (POD) 4. To understand the mechanism by which VEGF accelerates lung growth, proliferation of human bronchial epithelial cells (HBEC) was assessed in a co-culture model with lung microvascular endothelial cells (HMVEC-L) treated with and without VEGF (10 ng/mL). The assay was then repeated with a heparin-binding EGF-like growth factor (HB-EGF) neutralizing antibody ranging from 0.5–50 μg/mL. Compared to control mice, the VEGF-treated group displayed significantly higher lung volume (P = 0.001) and alveolar count (P = 0.005) on POD 4. VEGF treatment resulted in increased pulmonary expression of HB-EGF (P = 0.02). VEGF-treated HMVEC-L increased HBEC proliferation (P = 0.002) while the addition of an HB-EGF neutralizing antibody at 5 and 50 μg/mL abolished this effect (P = 0.01 and 0.002, respectively). These findings demonstrate that nasal delivery of VEGF enhanced CLG. These effects could be mediated by a paracrine mechanism through upregulation of HB-EGF, an epithelial cell mitogen.

13 February 2020 in Amyloid
Verified
Journal Article
Closed access
JVJacqueline Vuong
Jacqueline Vuong
ASAvinainder Singh
Avinainder Singh
RFRodney H. Falk
Rodney H. Falk
RMRaina Merchant
Raina Merchant
SDSharmila Dorbala
Sharmila Dorbala
(2020). Geographic variation in public interest about amyloidosis in the United States and English speaking countries. Amyloid. Ahead of Print.